2020
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902
Foss FM, Wang XV, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, Wagner H, Strair RK, Hogan WJ, Sprague KA, Lazarus HM, Litzow MR, Tallman MS, Horning SJ. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion 2020, 60: 1867-1872. PMID: 32654201, PMCID: PMC7606221, DOI: 10.1111/trf.15798.Peer-Reviewed Original ResearchConceptsReduced intensity conditioning regimenIntensity conditioning regimenExtracorporeal photopheresisConditioning regimenChronic extensive GVHDTotal body irradiationChronic graftECOG-ACRINExtensive GVHDGVHD prophylaxisHost diseaseMycophenolate mofetilCell infusionMulticenter trialTolerogenic stateAggressive lymphomaBody irradiationMedian timeMyelodysplastic syndromeGrade 3Day 100PatientsCellular therapyConsecutive daysAdequate engraftment
2004
Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome
Foss FM. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. Best Practice & Research Clinical Haematology 2004, 17: 573-584. PMID: 15494295, DOI: 10.1016/j.beha.2004.08.009.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeAnti-vascular endothelial growth factorChemotherapeutic agentsAllogeneic bone marrow transplantationReceptor tyrosine kinase inhibitorsGrowth factorTransplant conditioning regimensBone marrow transplantationTyrosine kinase inhibitorsClonal hematopoietic disordersEndothelial growth factorNovel chemotherapeutic agentsMatrix metalloproteinase inhibitorsFarnesyl transferase inhibitorsIntensive chemotherapyConditioning regimensSupportive careFavorable cytogeneticsPrognostic factorsAntimetabolite therapyMarrow transplantationMDS patientsTreatment paradigmClinical trialsProtein kinase C inhibitor